Genome-wide association analyses of chronotype in 697,828 individuals provides new insights into circadian rhythms in humans and links to disease

Samuel E. Jones1*, Jacqueline M. Lane2,3,4*, Andrew R. Wood1*, Vincent T. van Hees5, Jessica Tyrrell1, Robin N. Beaumont1, Aaron R. Jeffries1, Hassan S. Dashti2,4, Melvyn Hillsdon6, Katherine S. Ruth1, Marcus A. Tuke1, Hanieh Yaghoobkar1, Seth A. Sharp1, Yingjie Ji1, James W. Harrison1, Amy Dawes1, Enda M. Byrne7, Henning Tiemeier8,9, Karla V. Allebrandt10, Jack Bowden11,12, David W. Ray13,14, Rachel M. Freathy1, Anna Murray1, Diego R. Mazzotti15, Philip R. Gehrman16, the 23andMe Research Team17, Deborah A. Lawlor11,12*, Timothy M. Frayling1*, Martin K. Rutter13,14,18*, David A. Hinds17*, Richa Saxena2,3*, Michael N. Weedon1*

*Equal Contributions

Affiliations

1Genetics of Complex Traits, University of Exeter Medical School, Exeter, United Kingdom
2Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
3Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
4Broad Institute, Cambridge, MA, USA
5Netherlands eScience Center, Amsterdam, The Netherlands
6Sport and Health Sciences, College of Life and Environmental Sciences, University of Exeter, Exeter, UK
7Queensland Brain Institute, The University of Queensland, Brisbane, Australia.
8Department of Epidemiology, Erasmus Medical Center, Rotterdam, Netherlands.
9Department of Psychiatry, Erasmus Medical Center, Rotterdam, Netherlands.
10Medical Faculty, Ludwig-Maximilians-University of Munich, Germany.
11Population Health Sciences, Bristol Medical School, University of Bristol, UK
12MRC Integrative Epidemiology Unit at the University of Bristol, UK
13Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
14Division of Endocrinology, Diabetes & Gastroenterology, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, UK
15Center for Sleep and Circadian Neurobiology, University of Pennsylvania, Philadelphia, PA, United States
16Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
1723andMe Inc., 899 W. Evelyn Avenue, Mountain View, California 94041, USA
18Manchester Diabetes Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
Abstract

Using data from 697,828 research participants from 23andMe and UK Biobank, we identified 351 loci associated with being a morning person, a behavioural indicator of a person’s underlying circadian rhythm. These loci were validated in 85,760 individuals with activity-monitor derived measures of sleep timing: the mean sleep timing of the 5% of individuals carrying the most “morningness” alleles was 25.1 minutes (95% CI: 22.5, 27.6) earlier than the 5% carrying the fewest. The loci were enriched for genes involved in circadian rhythm and insulin pathways, and those expressed in the retina, hindbrain, hypothalamus, and pituitary (all FDR<1%). We provide some evidence that being a morning person was causally associated with reduced risk of schizophrenia (OR: 0.89; 95% CI: 0.82, 0.96), depression (OR: 0.94; 95% CI: 0.91, 0.98) and a lower age at last childbirth in women (β: -0.046 years; 95% CI: -0.067, -0.025), but was not associated with BMI (β: -4.6x10⁻⁴; 95% CI: -0.044, 0.043) or type 2 diabetes (OR: 1.00; 95% CI: 0.91, 1.1). This study offers new insights into the biology of circadian rhythms and disease links in humans.
Introducion

Circadian rhythms are fundamental cyclical processes that occur in most living organisms, including humans. These daily cycles affect a wide range of molecular and behavioural processes, including hormone levels, core body temperature and sleep-wake patterns\(^1\). Chronotype, often referred to as circadian preference, describes an individual’s proclivity for earlier or later sleep timing and is a physical and behavioural manifestation of the coupling between internal circadian cycles and the need for sleep, driven by sleep homeostasis. Significant natural variation exists amongst the human population with chronotype often measured on a continuous scale\(^2\), though individuals are traditionally separated into “morning people” (or “larks”) who prefer going to bed and waking earlier, “evening people” (or “owls”) who perform best with a later bedtime and later rising time, and “intermediates” who lie between the two extremes\(^3,4\). Age and gender, as well as environmental light levels explain a substantial proportion of variation in chronotype, but genetic variation is also an important contributor\(^5,6,7,8\).

There is evidence that alterations to circadian timing are linked to disease development, particularly metabolic and psychiatric disorders\(^9,10\). Animal model studies have shown that mutations in, and altered expression of, key circadian rhythm genes can cause obesity, hyperglycaemia and defective beta-cell function leading to diabetes\(^11–13\). In humans, there are many reported associations between disrupted circadian rhythms and disease\(^14,15\), but the evidence for a causal role of chronotype on disease is limited\(^16\). For example, evening people have an increased frequency of obesity\(^17\), type 2 diabetes\(^18\) and depression\(^19\) independent of sleep disturbance, and studies of shift workers show an increased risk of diabetes, depression and other diseases\(^20\). However, these associations could be explained by reverse causality (diseases affecting sleep patterns or dictating job options) or confounding (common risk factors influencing both chronotype and disease). Genetic analyses identifying variants robustly associated with putative risk factors, such as chronotype, can improve causal understanding by providing genetic instruments for use in Mendelian Randomization (MR) analyses, which minimise the effect of both reverse causality and bias caused by confounding. Identifying genetic variants associated with chronotype and sleep timing will also provide new insights into the biological processes underlying circadian rhythms and sleep homeostasis.

Three previous genome-wide association studies (GWAS)\(^21–23\), using a maximum of 128,286 individuals, identified a total of 22 variants associated with self-report chronotype. In this study, we performed a GWAS meta-analysis of a substantially expanded set of 697,828 individuals, including 248,098 participants from 23andMe Inc., a personal genetics company.
and 449,734 participants from UK Biobank. We were able to validate self-report chronotype genetic associations using estimates of sleep midpoint derived from activity monitors worn continuously for up to 7 days by 85,760 UK Biobank participants. We offer new insights into the genetics behind natural variation in chronotype and identify causal relationships between variation in human circadian rhythms and multiple traits and diseases.

Results

351 loci associated with morning chronotype from a GWAS meta-analysis including 697,828 individuals. We performed a GWAS of self-report chronotype using 11,977,111 imputed variants in 449,734 individuals of European ancestry from the UK Biobank and 11,947,421 variants in 248,098 European-ancestry 23andMe research participants. We identified 351 independent loci at \( P<5\times10^{-8} \), of which 258 reached \( P<6\times10^{-9} \), a correction for the significance threshold based on permutation testing (Supplementary Methods). The meta-analysis and individual study results are shown in Figure 1 and Supplementary Table 1. Conditional analysis identified 49 loci with multiple independent signals (Supplementary Table 2). A sensitivity analysis was performed in the UK Biobank data alone, excluding shift workers and those either on medication or with disorders affecting sleep (see the Methods section and Supplementary Methods for details). Effect sizes were similar to those in the full UK Biobank GWAS (Supplementary Table 1 and Supplementary Figure 1).

Validation of chronotype associated variants in 85,760 individuals with activity monitor data. Self-report assessments of sleep and chronotype can be subject to reporting bias\(^{24-27}\). To validate the self-report chronotype associations using activity monitor data available in UK Biobank, we tested the association of the chronotype-associated variants with derived estimates of sleep timing, duration and quality and estimates of circadian activity rhythms. Derived phenotypes included sleep efficiency, sleep duration and timings of sleep midpoint, midpoint of the least active 5 hours of the day (L5 timing) and midpoint of the most active 10 hours of the day (M10 timing). Summary statistics of these derived phenotypes and their associations with self-report morningness are presented in Supplementary Table 3, and their associations with the newly identified chronotype SNPs are provided in Supplementary Table 4. To avoid inflation of associations with our GRS, we performed an additional meta-analysis excluding all UK Biobank individuals with activity monitor data. Of the 292 lead chronotype variants reaching \( P<5\times10^{-8} \) from this meta-analysis that were available in the UK Biobank imputed genotype data, 258 had a consistent direction of effect for sleep midpoint (two-sided binomial test \( P=8.8\times10^{-44} \)), 262 with L5 timing \( (P=2.1\times10^{-47}) \) and 260 with M10 timing \( (P=1.5\times10^{-45}) \). A genetic risk score (GRS) of these 292 variants was associated with earlier sleep midpoint, L5 timing and M10 timing \( (P=4\times10^{-26}) \).
proinsulin levels with hours reported in the advancing sleep timing morningness syndrome MEIS1 and HTR6 previously reported most amongst the associated loci. Variants associated with circadian rhyt
to a peak of activity at similar effect of 26.1 minutes (95% CI: 23.1, 29.2) was seen for M10 timing carrying the fewest morningness had L
monitor derived (associated with earlier sleep midpoint (96/109; P=8.3x10^{-17}), with a GRS derived using these variants also being strongly associated with earlier sleep midpoint (P=3.3x10^{-72}), L5 timing (P=2x10^{-106}) and M10 timing (P=4.9x10^{-69}) and not with the other measures (Supplementary Table 5). Using the activity-monitor derived estimates of sleeping timing, the 5% of individuals carrying the most “morningness” alleles at the 292 associated loci (and weighted by self-reported effect size) had L5 timing shifted, on average, by 25.1 minutes (95% CI: 22.5, 27.6) compared to the 5% carrying the fewest morningness alleles: a mean L5 time of 03:06 rather than 03:32. A similar effect of 26.1 minutes (95% CI: 23.1, 29.2) was seen for M10 timing, corresponding to a peak of activity at 13:29 for the 5% of people carrying the most morningness alleles as opposed to 13:55 for those carrying the least.

**Variants associated with circadian rhythms, obesity and insulin secretion are amongst the associated loci.** Well-documented circadian rhythm genes were among the most strongly associated loci (Supplementary Table 1). These genes included the previously reported loci containing RGS16, PER2, PER3, PIGK/AK5, INADL, HCRTR2 and HTR6^{21-23}, and newly associated loci containing known circadian rhythm genes PER1, CRY1 and ARNTL (Supplementary Figure 2). Additional associations were identified within MEIS1, BTBD9 and PTPRD, three of four genes currently implicated in restless legs syndrome (RLS)\(^{26}\) though the reported lead RLS variants did not reach genome-wide significance. At the PER3 locus, two highly correlated low frequency missense variants (rs150812083 and rs139315125, MAF=0.5%), previously reported to be a monogenic cause of familial advanced sleep phase syndrome\(^{29}\), were associated with self-reported morningness (OR=1.44 for minor allele; P=2x10^{-36}) but with a lower magnitude of effect on sleep timing than expected in the activity-monitor derived measures of chronotype, advancing sleep timing by only 8 minutes (95% CI: 4, 13, P=4.3x10^{-4}) as opposed to the 4.2 hours reported in the previous study\(^{26}\). The allele in FTO (rs1558902) previously associated with higher BMI\(^{30,31}\) was also associated with being a morning person (OR=1.04, P= 4.9x10^{-32}). A missense variant in the MADD gene (rs35233100) previously associated with lower proinsulin levels\(^{32}\) (but not type 2 diabetes) was strongly associated with eveningness (OR= 1.05, P=4.4x10^{-12}).
**Circadian rhythm, insulin pathway and brain and pituitary expressed genes are strongly enriched at the associated loci.** We next used MAGMA\textsuperscript{33,34}, PASCAL\textsuperscript{35}, MAGENTA\textsuperscript{36} and DEPICT\textsuperscript{37} to identify biological pathways and tissues enriched for genes at the associated loci (Supplementary Tables 6-11). We identified strong enrichment of the circadian rhythm and insulin-regulation pathways (FDR<5\%), as well as G protein signalling and activation, (Figures 2 and 3) and enrichment of genes expressed in tissues of the brain, pituitary and retina, amongst the associated loci (Figure 4, Supplementary Tables 7 and 11).

**Integration of GWAS data with RNAi data highlights potentially causal genes at associated loci.** We next assessed the overlap of genes at the chronotype associated loci with 343 putative clock genes identified from RNAi knockdown experiments in a human cellular clock model\textsuperscript{38}. Of 353 genes mapped to the chronotype-associated loci at P<0.05 by DEPICT, there was no enrichment of the genes identified in the RNAi screen, with only 6 of the 353 genes overlapping (P=0.16). However, the overlapping genes included \textit{FBXL3}, known to have a role in circadian oscillations through ubiquitination and degradation of \textit{CRY1} and \textit{CRY2}, as well as \textit{GFAP}, encoding a filament protein important in the development of astrocytes in the central nervous system (Supplementary Table 12).

**Chronotype is heritable and demonstrates strong genetic correlation with several metabolic and psychiatric traits.** Using LD score regression, we estimated the heritability of chronotype to be 0.106 (0.003) in the meta-analysis. This compares to the heritability of 0.135 (0.001) estimated by BOLT-LMM in the UK Biobank data alone. We also performed LD-score regression analyses against a range of other diseases and traits where GWAS summary statistics are publicly available (Supplementary Table 13). The most genetically correlated trait was subjective well-being, which was positively correlated with being a morning person (r\textsubscript{G}=0.17, P=6x10\textsuperscript{-9}). Psychiatric traits schizophrenia (r\textsubscript{G}=-0.11, P=1x10\textsuperscript{-7}), depressive symptoms (r\textsubscript{G}=-0.16; P=2x10\textsuperscript{-6}), major depressive disorder (r\textsubscript{G}=-0.19; P=3x10\textsuperscript{-5}) and intelligence (r\textsubscript{G}=-0.11; P=8x10\textsuperscript{-5}) were all negatively correlated with the morning chronotype. Metabolic traits fasting insulin (r\textsubscript{G}=-0.09, P=0.03) and HOMA-IR (r\textsubscript{G}=-0.12, P=0.009) were nominally negatively correlated with being a morning person. BMI (r\textsubscript{G}=0.007, P=0.74) and T2D (r\textsubscript{G}=0.02, P=0.60) were not genetically correlated.

**Mendelian randomisation (MR) analyses provide evidence for a causal link between chronotype and mental health and fecundity.** Altered sleep patterns are associated with many disease and health outcomes in observational studies but there is limited evidence for
causality. To test for a causal effect of chronotype on disease and related outcomes we performed Mendelian randomization analyses against 367 metabolic, psychiatric and other phenotypes in the UK Biobank and with external GWAS datasets using MR Base\textsuperscript{39} and the corresponding R package TwoSampleMR\textsuperscript{40}. We used 109 (of the total 115) variants identified at \(P<5\times10^{-8}\) in the 23andMe study alone (Supplementary Table 14) for the UK Biobank MR analyses. For most traits, even with strong observational associations, we did not find evidence of a causal effect of genetically influenced chronotype. For example, there was no evidence that morningness or eveningness leads to higher BMI (\(P=0.94\) in UK Biobank) or risk of Type 2 diabetes (\(P=0.83\)) (Supplementary Figures 3 and 4 and Supplementary Table 15). A small number of Mendelian randomisation tests survived correction for multiple testing, including morningness leading to a younger age at which women had their last child: a genetically-determined unit log-odds increase in morningness (equivalent to a morningness odds ratio of \(~2.7\) was associated with a 16.8-day (95% CI: 12.8, 24.5) younger age of last child birth (IVW \(P=3\times10^{-5}\)) (Supplementary Figure 5). There was nominal evidence that morningness causally decreases risk of schizophrenia, depression and multiple pregnancy loss: a genetically-determined unit log-odds increase in morningness was associated with odds ratios of 0.89 (0.82, 0.96; IVW \(P=0.004\)), 0.94 (0.91, 0.98; IVW \(P=0.002\)) and 0.91 (0.86, 0.96; IVW \(P=0.002\)) respectively (Supplementary Figures 6-8, Supplementary Tables 15 and 16).

**Nominal evidence that type 2 diabetes, insulin secretion and BMI causally influence chronotype.** We next used Mendelian randomisation to test whether or not disease related traits could alter chronotype (Supplementary Table 17). We selected 40 traits where large-scale GWAS had identified multiple robustly associated SNPs and where the traits have been associated with chronotype in the literature or were observationally associated in the UK Biobank study. We found only nominal evidence that diseases and related traits alter chronotype: a genetically determined 1 unit log odds increase in type 2 diabetes, 1 SD increase in favourable adiposity\textsuperscript{41} (increased subcutaneous-to-visceral adiposity but lower insulin levels), 1 SD increase in insulin secretion and 1 SD increase in BMI were associated with morningness odds ratios of 1.02 (95%CI: 1.00, 1.04; IVW \(P=0.01\)), 0.86 (0.76, 0.97; IVW \(P=0.02\)), 1.10 (1.01, 1.20; IVW \(P=0.04\)) and 1.06 (1.00, 1.13; IVW \(P=0.05\)) respectively. For BMI, the association did not remain after excluding the chronotype \(FTO\) variant which has a primary effect on BMI (OR = 1.02; 95%CI: 0.96, 1.08; IVW \(P=0.58\)) (Supplementary Figures 9-11).
**Discussion**

We performed a GWAS of chronotype in 697,828 individuals from 23andMe and the UK Biobank study and increased the number of associated loci from 22 to 351. The variants associated with self-report chronotype were also associated with activity-monitor derived estimates of sleep timing but not measures of sleep quantity or quality. The validation using activity-based estimates of sleep timing was important because self-report traits may result in reporting biases. Our data suggests that self-report sleep measures strongly relate to an individual’s sleep timing and therefore provide valid instruments for MR and compelling insights into circadian biology.

Chronotype-associated loci were strongly enriched for known circadian genes, as well as genes more distally involved in circadian processes. Variants at these loci included the low frequency (MAF=0.5%) coding variants (P415A/H417R) in PER3 previously identified as a cause of familial advanced sleep phase syndrome\(^29\). Although it had a large effect on chronotype (OR=1.44), we found that the minor allele of this variant was associated with an average earlier sleep timing of only 8 minutes, suggesting this is a low penetrance disease variant and not a monogenic cause of delayed sleep. By integrating information from tissue expression and previous RNAi experiments we identified additional genes likely to be involved in circadian timing, for example LSM7 which encodes core components of the spliceosomal U6 small nuclear ribonucleoprotein complex for which some previous studies have suggested a role in circadian timing\(^38,42\).

Despite a substantial body of observational epidemiology literature on the association between circadian rhythm variation and disease, we found no convincing evidence for a causal effect of morningness on many of these disorders in our MR analyses. Of the traits we tested, we found some evidence that being a morning person may result in a younger age at last childbirth and a reduced risk of multiple pregnancy losses, schizophrenia and depression. Although these results need replication, there is existing evidence of the relationship between circadian rhythms and fertility in women\(^43-45\), and between circadian rhythms and mental health suggesting that this an area for further investigation.

Previously reported observational associations of chronotype with metabolic diseases are particularly strong\(^46,47\), but we found no evidence for a causal effect of morningness on type 2 diabetes or BMI and could exclude the observational association effect sizes. We found nominal evidence of effects in the opposite direction. For example, MR analyses showed that there was nominal evidence of a causal role of higher T2D risk, and both higher insulin secretion and BMI, on being a morning person. This is exemplified by a missense variant in
the MADD gene (rs35233100) previously associated with lower proinsulin levels\textsuperscript{32} (but not type 2 diabetes) being associated with eveningness. The BMI association, however, appears to be driven by the obesity associated allele in FTO (rs1558902) previously associated with higher BMI\textsuperscript{30,31} being strongly associated with being a morning person. There is substantial evidence of a link between appetite, feeding and insulin pathways and circadian rhythms\textsuperscript{48,49} supported by our pathway analyses which demonstrates an enrichment of insulin secretion regulation pathways; however, it is unclear why the causal association is not seen in the opposite direction.

The response to UK Biobank participation was < 5% and this can result in bias, including in GWAS and MR\textsuperscript{50}. Here GWAS results replicated those of 23andMe, a study that may also suffer from selection bias but of a different nature to UK Biobank, and our MR results in UK Biobank were consistent with those from using two-sample MR in publicly-available aggregated data, based on consortia of studies that had considerably greater response rates.

In conclusion, we have identified hundreds of novel loci that regulate circadian rhythms and sleep timing in humans and provide new insights into the causal nature of the observational associations with disease.
Materials and Methods

Data availability
Summary statistics for the top 10,000 chronotype meta-analysis variants are provided in Supplementary Table 18 and the full set of UK Biobank-only chronotype and morning person GWAS summary statistics can be found at: http://www.t2diabetesgenes.org/data/.

Ethics Statement
Details of patient and public involvement in the UK Biobank are available online at www.ukbiobank.ac.uk/about-biobank-uk/ and https://www.ukbiobank.ac.uk/wp-content/uploads/2011/07/Summary-EGF-consultation.pdf. Participants were not involved in setting research questions or any outcome measures, nor were they involved in planning, design, recruitment for or implementation of this study. Participants also had no involvement in analysing data, interpreting results or preparing this manuscript. There are no specific plans to disseminate the results of the research to study participants, though the UK Biobank disseminates key findings from projects on its website.

Cohorts
The UK Biobank is described in detail elsewhere51. We used data on 451,454 individuals from the full UK Biobank data release that we identified as White European and that had genetic data available. To define a set of White Europeans, we performed Principal Components Analysis (PCA) in the 1000 Genomes (1KG) reference panel using a subset of variants that were of a high quality in the UK Biobank. We projected these principal components into the set of related UK Biobank participants to avoid the relatedness confounding the principal components. We then adopted a k-means clustering approach to define a European cluster, initializing the ethnic centres defined by the population-specific means of the first four 1KG principal components. This analysis was performed only within individuals self-reporting as “British”, “Irish”, “White” or “Any other white background. Because association analyses are performed using linear mixed-model (LMM) method, we included related individuals.

We used summary statistics from a morning chronotype GWAS performed by 23andMe of 248,100 (N\text{case}=120,478; N\text{control}=127,622) participants with a minimum of 97% European ancestry. GWAS analysis was performed in a maximal set of unrelated participants, where pairs of individuals were considered related if they shared 700cM IBD of genomic segments, roughly corresponding to first cousins in an outbred population. The 23andMe cohort is described in more detail elsewhere21.
Activity Monitor Data

A subset of the UK Biobank cohort was invited to wear a wrist-worn activity monitor for a period of one week. Individuals were mailed the device and asked to wear it continuously for seven days, including while bathing, showering and sleeping. In total, 103,720 participants returned their activity monitor devices with data covering at least three complete 24-hour periods. We downloaded the raw activity monitor data (data-field 90001) for these individuals, in the form of binary Continuous Wave Accelerometer (cwa) files. Further information, along with details of centrally-derived variables, is available elsewhere\(^\text{52}\).

Detailed protocol information can be found online at http://biobank.ctsu.ox.ac.uk/crystal/docs/PhysicalActivityMonitor.pdf and a sample instruction letter at http://biobank.ctsu.ox.ac.uk/crystal/images/activity_invite.png (UKB Resources 131600 and 141141, respectively; both accessed January 30\(^\text{th}\) 2018). We converted the .cwa files to .wav format using the open-source software “omconvert”, recommended by the activity monitor manufacturers Axivity, which is available online (see https://github.com/digitalinteraction/openmovement/tree/master/Software/AX3/omconvert).

To process the raw accelerometer data, we used the freely available R package “GGIR” (v1.5-12)\(^\text{53,54}\). The list of our GGIR settings is provided in the Supplementary File and the full list of variables produced by GGIR can be found in the CRAN GGIR reference manual (see https://cran.r-project.org/web/packages/GGIR/GGIR.pdf).

Genotyping and quality control

The 23andMe cohort was genotyped on one of four custom arrays: the first two were variants of the Illumina HumanHap550+ BeadChip (\(N_{\text{case}}=4,966; N_{\text{control}}=5,564\)), the third a variant of the Illumina OmniExpress+ BeadChip (\(N_{\text{case}}=53,747; N_{\text{control}}=61,637\)) and the fourth a fully custom array (\(N_{\text{case}}=61,765; N_{\text{control}}=60,421\)). Successive arrays contained substantial overlap with previous chips. These genotypes were imputed to ~15.6M variants using the September 2013 release of the 1000 Genomes phase 1 reference panel. For analyses, we used ~11.9M imputed variants with imputation \(r^2 \geq 0.3\), MAF \(\geq 0.001\) (0.1%) and that showed no sign of batch effects.

The UK Biobank cohort was genotyped on two almost identical arrays. The first ~50,000 samples were genotyped on the UK BiLEVE array and the remaining ~450,000 samples were genotyped on the UK Biobank Axiom array in two groups (interim and full release). A total of 805,426 directly-genotyped variants were made available in the full release. These variants were centrally imputed to ~93M autosomal variants using two reference panels: a combined UK10K and 1000 Genomes panel and the Haplotype Reference Consortium.
For all analyses, we used ~12.0M Haplotype Reference Consortium (HRC) imputed variants with an imputation $r^2 \geq 0.3$, MAF $\geq 0.001$ (0.1%) and with a Hardy-Weinberg equilibrium $P>1\times10^{-12}$. We excluded non-HRC imputed variants on advice from the UK Biobank imputation team. Further details on the UK Biobank genotyping, quality control and imputation procedures can be found elsewhere\textsuperscript{55}.

**Self-Reported Phenotypes**

*Chronotype (UK Biobank)*

The UK Biobank collected a single self-reported measure of Chronotype (“Morning/evening person (chronotype)”; data-field 1180). Participants were prompted to answer the question "Do you consider yourself to be?" with one of six possible answers: “Definitely a ‘morning’ person”, “More a ‘morning’ than ‘evening’ person”, “More an ‘evening’ than a ‘morning’ person”, “Definitely an ‘evening’ person”, “Do not know” or “Prefer not to answer”, which we coded as 2, 1, -1, -2, 0 and missing respectively. Prior to association testing, we adjusted the phenotype for age, gender and study centre (categorical). Of the 451,454 white European participants with genetic data, 449,734 were included in the GWAS (had non-missing phenotype and covariates).

*Morning Person (UK Biobank)*

In order to provide interpretable odds ratios for our genome-wide significant variants, we also defined a binary phenotype using the same data-field as for Chronotype. Participants answering “Definitely an ‘evening’ person” and “More an ‘evening’ than a ‘morning’ person” were coded as 0 (controls) and those answering “Definitely a ‘morning’ person” and “More a ‘morning’ than ‘evening’ person” were coded as 1 (cases). Participants answering “Do not know” or “Prefer not to answer” were coded as missing. A total of 403,195 participants were included in the GWAS (252,287 cases and 150,908 controls).

*Morning Person (23andMe)*

Responses to two identical questions were used to define the dichotomous morning person phenotype in the 23andMe cohort, with one question having a wider selection of neutral options. More details are given in Supplementary Table 2 of the 23andMe morning person GWAS\textsuperscript{21}. Morning people were coded as 1 (cases; N=120,478) and evening people were coded as 0 (controls; N=127,622).

**Activity monitor Phenotypes**

*Identifying the sleep period window*
The software package GGIR\textsuperscript{54,56} produces quantitative and timing measures relating to both activity levels and sleep patterns, with a day-by-day breakdown, as well averages across the period of wear. A new algorithm, implemented in version 1.5-12 of the GGIR R package and validated using PSG in an external cohort\textsuperscript{57}, allows for detection of sleep periods without the use of a sleep diary and with minimal bias. Briefly, for each individual, median values of the absolute change in z-angle (representing the dorsal-ventral direction when the wrist is in the anatomical position) across 5-minute rolling windows were calculated across a 24-hour period, chosen to make the algorithm insensitive to activity monitor orientation. The 10th percentile was incorporated into the threshold to distinguish movement from non-movement. Bouts of inactivity lasting ≥30 minutes are recorded as inactivity bouts. Inactivity bouts that are <60 minutes apart are combined to form inactivity blocks. The start and end of longest block defines the start and end of the sleep period time-window (SPT-window).

**Activity monitor exclusions and adjustments**

The UK Biobank made multiple activity monitor data-quality variables available. From our activity monitor phenotypes, we excluded 4,925 samples with a non-zero or missing value in data field 90002 ("Data problem indicator"). We then excluded any individuals with the "good wear time" flag (field 90015) set to 0 (No), "good calibration" flag (field 90016) set to 0 (No), "calibrated on own data" flag (field 90017) set to 0 (No), "data recording errors" (field 90182) \(> 788 \ (Q_3 + 1.5\times IQR)\) or a non-zero count of "interrupted recording periods" (field 90180).

Phenotypes determined using the SPT-window (all phenotypes except L5 and M10 timing) had additional exclusions based on short (<3 hours) and long (>12 hours) mean sleep duration and too low (<5) or too high (>30) mean number of sleep episodes per night (see below). These additional exclusions were to ensure that individuals with extreme (outlying), and likely incorrect, sleep characteristics were not included in any subsequent analyses. Prior to association testing, we adjusted all phenotypes for age activity monitor worn (derived from month and year of birth and date activity monitor worn), gender, season activity monitor worn (categorical; winter, spring, summer or autumn; derived from date activity monitor worn) and number of valid measurements (SPT-windows for sleep phenotypes, number of valid days for diurnal inactivity or number of L5 or M10 detections).

**L5 and M10 timing (UK Biobank)**

L5 and M10 refer to the least-active five and the most-active ten hours of each day, and are commonly studied measures relating to circadian activity and sleep. L5 (M10) defines a five-hour (ten-hour) daily period of minimum (maximum) activity, as calculated by means of a moving average with a five-hour (ten-hour) window. We defined our L5 (M10) timing phenotype as the number of hours elapsed from the previous midnight to the L5 (M10)
midpoint, averaged over all valid wear days. Of the 103,711 participants with activity monitor data, there were 85,205 and 85,670 with valid L5 and M10 timing measures respectively, covariates and genetic data. Basic summaries of these and other raw activity monitor phenotypes are given in Supplementary Table 3.

Sleep midpoint (UK Biobank)
Sleep midpoint was calculated as the time directly between the start and end of the SPT-window, and is defined as the number of hours elapsed since the previous midnight (e.g. 02:30 = 26.5). Our sleep midpoint phenotype represented the average over all valid sleep periods. After exclusions and adjustments, 84,810 participants had valid sleep midpoint, covariates and genetic data.

Sleep duration (UK Biobank)
Sleep episodes within the SPT-window were defined as periods of at least 5 minutes with no change larger than 5° associated with the z-axis of the activity monitor, as described previously. The summed duration of all sleep episodes provided the sleep duration for a given SPT-window. We took both the mean and standard deviation of sleep duration across all valid SPT-windows to provide a measure of average sleep quantity and a measure of variability. After exclusions and adjustments, we had 85,449 (84,441) participants with valid sleep duration mean (S.D.), covariates and genetic data.

Sleep efficiency (UK Biobank)
This was calculated as a ratio of sleep duration (defined above) to SPT-window duration. The phenotype represented the mean across all valid SPT-windows and after exclusions and adjustments, left us with 84,810 participants with valid sleep efficiency, covariates and genetic data.

Number of sleep episodes (UK Biobank)
This is defined as the number of sleep episodes separated by last least 5 minutes of wakefulness within the SPT-window. The phenotype represents the mean across all SPT-windows and can be interpreted as a measure of sleep disturbance or fragmentation. After exclusions and adjustments, we had 84,810 participants with valid sleep efficiency, covariates and genetic data.

Diurnal inactivity duration (UK Biobank)
The total daily duration of estimated bouts of inactivity that fall outside of the SPT-window. This includes both periods of inactivity and sleep (naps), as it is impossible to separate these
without detailed activity diaries. The phenotype is calculated as the mean across all valid days and, after exclusions and adjustments, we were left with 84,757 participants with a valid measure, covariates and genetic data.

**Genome-wide Association Analysis**

We performed all association test using BOLT-LMM\(^{58}\) v2.3, which applies a linear mixed model (LMM) to adjust for the effects of population structure and individual relatedness, and allowed us to include all related individuals in our white European subset, boosting our power to detect associations. This meant a sample size of up to 449,734 individuals, as opposed to the set of 379,768 unrelated individuals. BOLT-LMM approximates relatedness within a cohort by using LD blocks and avoids the requirement of building a genetic-relationship matrix (GRM), with which calculations are intractable in cohorts of this size. From the ~805,000 directly-genotyped (non-imputed) variants available, we identified 524,307 “good-quality” variants (bi-allelic SNPs; MAF≥1%; HWE \(P>1\times10^{-6}\); non-missing in all genotype batches, total missingness<1.5% and not in a region of long-range LD\(^{59}\)) for inclusion in BOLT-LMM’s mixed model, and we used the 1000 Genomes European LD-Score table provided with the software for information on LD structure. We forced BOLT-LMM to apply a non-infinitesimal model, which provides better effect size estimates for variants with moderate to large effect sizes, in exchange for increased computing time. Prior to association testing, continuous phenotypes were first adjusted for relevant covariates, as indicated above, and at runtime we included “release” (categorical; UKBiLEVE array, UKB Axiom array interim release and UKB Axiom array full release) as a further covariate. The binary morning person phenotype was adjusted at runtime for age, gender, study centre and release.

In the 23andMe morning person GWAS, the summary statistics were generated through logistic regression (using an additive model) of the phenotype against the genotype, adjusting for age, gender, the first four principal components and a categorical variable representing genotyping platform. Genotyping batches in which particular variants failed to meet minimum quality control were not included in association testing for those variants, resulting in a range of sample sizes over the whole set of results. A \(\lambda_{GC}\) of 1.325 was reported for this GWAS.

**Sensitivity Analysis**

To avoid issues with stratification, we performed a sensitivity GWAS, in UK Biobank alone, to assess whether any of the associations were driven by a subset of the cohort with specific conditions. We excluded those reporting shift or night shift work at baseline, those taking...
medication for sleep or psychiatric disorders and those with either with a HES ICD10 or self-reported diagnosis of depression, schizophrenia, bipolar disorder, anxiety disorders or mood disorder (see Supplementary Methods for further details). Results for the 341 lead chronotype variants available in the UK Biobank are provided in Supplementary Table 1 alongside the main meta-analysis results.

**Meta-analysis of GWAS Results**

Meta-analysis was performed using the software package METAL$^{60}$. To obtain the largest possible sample size, and thus maximising statistical power, we performed a sample-size meta-analysis, using the results from the UK Biobank chronotype GWAS and the 23andMe morning person GWAS. Genomic control was not performed on each set of summary statistics prior to meta-analysis but instead the meta-analysis chi-squared statistics were corrected using the LD score intercept ($I_{LDSC} = 1.0829$), calculated by the software LDSC, as using $\lambda_{GC}$ is considered overly conservative and the LD score intercept better captures inflation due to population stratification$^{61}$. For interpretable results, we reported the odds ratio from a secondary effect size meta-analysis between our dichotomous UK Biobank morning person GWAS and the 23andMe morning person GWAS. The primary meta-analysis produced results for 15,880,618 variants in up to 697,828 individuals.

**Post-GWAS Analyses**

**Pathway analysis and tissue-enrichment**

We used MAGENTA$^{36}$, DEPICT$^{37}$, PASCAL$^{35}$ and MAGMA$^{33}$. For MAGENTA and DEPICT, we included all variants from the meta-analysis, whereas for PASCAL, we included only those with an RSID as the software assigns variants to genes using their RSID. For the MAGENTA analysis, we used upstream and downstream limits of 110Kb and 40Kb to assign variants to genes by position, we excluded the HLA region from the analysis and set the number of permutations for gene-set enrichment analysis (GSEA) to 10,000. For DEPICT, we used the default settings and the annotation and mapping files provided with the software.

**Genetic correlation and heritability analyses**

We used the LD Score Regression (LDSC) software, available at https://github.com/bulik/ldsc/, to quantify the genetic overlap between the trait of interest and 222 traits with publicly available GWA data. Details of methodology are available elsewhere$^{62}$. We considered any correlation as statistically significant if it had a Bonferroni corrected $P<0.05$. 
**Mendelian Randomisation Analyses**

Given the large number of studies reporting multi-variable associations of chronotype and sleep traits with multiple health outcomes, we undertook MR analyses to explore both the effect of chronotype on different outcomes and the effect of different exposures on chronotype as an outcome. These two-sample MR analyses can be summarised by:

1. Chronotype exposure using 109 variants and effect sizes discovered in 23andMe against 250 outcomes from unpublished parallel UK Biobank GWAS (*Supplementary Table 15*).
2. Chronotype exposure using 351 variants and effect sizes discovered in the meta-analysis against 671 outcomes from published studies (*Supplementary Table 16*).
3. 39 exposures using variants from published studies against UK Biobank chronotype as an outcome (*Supplementary Table 17*).

Analyses 1 and 3 were performed using a custom pipeline (designed to use only summary data of both exposure and outcome) in which we tested four MR methods:

a. Inverse-variance weighting (IVW)

b. MR-Egger

c. Weighted median (WM) estimation

d. Penalised weighted median (PWM) estimation

Analysis 2 was performed using the R package TwoSampleMR using aggregated summary statistics available through the MR-Base platform. We implemented the same four methods as with analyses 1 and 3, and also included the MR-Egger bootstrap to provide better estimates of the effect sizes and standard errors as compared to the MR-Egger method.

Analyses 1 and 2 both investigated the effect of chronotype on different traits or diseases, yet they had different strengths. Analysis 1 took advantage of the availability of summary level data in ~39 million HRC-imputed positive-strand SNPs for multiple outcomes. This means that the statistical power of the MR tests was less variable from one phenotype to another, as the number of genetic chronotype instruments used was consistent across all outcomes. The caveat was that we had to use 109 variants (and effects) discovered in 23andMe (and not UK Biobank) to avoid biasing our results away from the null, reducing the number of chronotype instruments and thus reducing our power to detect causal associations. As analysis 2 relied upon published summary statistics, we were able to use all 351 variants discovered in the chronotype meta-analysis as genetic instruments (thus providing greater statistical power), though the number of these available in the summary statistics of published GWAS varied greatly, leading to a large heterogeneity in the statistical...
power available to detect causal associations with the different outcomes. Consistent
evidence of association for the same outcomes between analyses 1 and 2 would provide
strong evidence for causality.

We used the inverse variance weighted approach as our main analysis method and MR-
Egger, weighted median estimation and penalised weighted median estimation as sensitivity
analyses in the event of unidentified pleiotropy of our genetic instruments. MR results may
be biased by horizontal pleiotropy, i.e. where the genetic variants that are robustly related to
the exposure of interest (here chronotype) independently influence the outcome, through
association with another risk factor for the outcome. IVW assumes that there is either no
horizontal pleiotropy (under a fixed effect model) or, if implemented under a random effects
model after detecting heterogeneity amongst the causal estimates, that:

i. The strength of association of the genetic instruments with the risk factor is not
correlated with the magnitude of the pleiotropic effects

ii. The pleiotropic effects have an average value of zero

MR-Egger provides unbiased causal estimates if just the first condition above holds, by
estimating and adjusting for non-zero mean pleiotropy. However, MR-Egger requires that the
InSIDE (Instrument Strength Independent of Direct Effect) assumption holds, in that it
needs the pleiotropy of the genetic instruments to be uncorrelated with the instruments’
effect on the exposure. The weighted median approach is valid if less than 50% of the
weight in the analysis stems from variants that are pleiotropic (i.e. no single SNP that
contributes 50% of the weight or a number of SNPs that together contribute 50% should be
invalid because of horizontal pleiotropy). Given these different assumptions, if all methods
are broadly consistent this strengthens our causal inference.

Acknowledgements

This research has been conducted using the UK Biobank Resource under Application
Number 9072. We would like to thank the research participants and employees of 23andMe
for making this work possible.

Contributor list for the 23andMe Research Team: Michelle Agee, Babak Alipanahi, Adam
Auton, Robert K. Bell, Katarzyna Bryc, Sarah L. Elson, Pierre Fontanillas, Nicholas A.
Furlotte, David A. Hinds, Karen E. Huber, Aaron Kleinman, Nadia K. Litterman, Jennifer C.
McCreight, Matthew H. McIntyre, Joanna L. Mountain, Elizabeth S. Noblin, Carrie A.M.
Northover, Steven J. Pitts, J. Fah Sathirapongsasuti, Olga V. Sazonova, Janie F. Shelton, Suyash Shringarpure, Chao Tian, Joyce Y. Tung, Vladimir Vacic, and Catherine H. Wilson.

**Funding Information.** S.E.J. is funded by the Medical Research Council grant MR/M005070/1. J.M.L is supported by the NIH grants F32DK102323 and 4T32HL007901. A.R.W., T.M.F and H.Y. are supported by the European Research Council grants: SZ-24550371-GLUCOSEGENES-FP7-IDEAS-ERC and 323195. J.T. is funded by a Diabetes Research and Wellness Foundation Fellowship. R.N.B. and R.M.F. are funded by the Wellcome Trust and Royal Society grant: 104150/Z/14/Z. R.M.F. is a Sir Henry Dale Fellow. H.S.D. and R.S. are supported by NIH grants R01DK107859, NIH R01 DK102696 and the MGH Research Scholar Fund. M.A.T., M.N.W. and A.M. are supported by the Wellcome Trust Institutional Strategic Support Award (WT097835MF). S.A.S. is funded by the NIH administrative supplement to the SEARCH study (NIH 3UC4DK108173-01S1). H.T. is funded by two Dutch Medical Research Foundation grants (016.VICI.170.200 and VIDI 017.106.370). J.B. and D.A.L. work in a Unit that receives support from the University of Bristol and UK Medical Research Council. D.A.L.’s contribution to this work is also supported by the European Research Council under the European Union’s Seventh Framework Programme (FP/2007-2013). D.W.R. is supported by the Wellcome Investigator award 107849/Z/15/Z. The funders had no influence on study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Duality of Interest.** D.A.L. receives support from Roche Diagnostics and Medtronic for research that is unrelated to this study. M.K.R. reports receiving honoraria and consulting fees from Novo Nordisk, Ascensia, Cell Catapult and Roche Diabetes Care. P.G. receives grant support from Merck, Inc. D.A.H. and the 23andMe Research Team are employees of, and hold stock or stock options in, 23andMe Inc.
Figure 1. Manhattan plot of the chronotype meta-analysis GWAS. The solid and dashed black lines respectively indicate typical and our permutation-testing genome-wide significance thresholds of \( P=5\times10^{-8} \) and \( P=6\times10^{-9} \).
Figure 2. Reactome gene sets overlapping Chronotype genes identified using positional and eQTL mapping (and not MAGMA) in FUMA’s GENE2FUNC process. Note that these results may differ to those produced by MAGMA.

Figure 3. WikiPathways gene sets overlapping Chronotype genes identified using positional and eQTL mapping (and not MAGMA) in FUMA’s GENE2FUNC process. Note that these results may differ to those produced by MAGMA.
Figure 4. MAGMA tissue expression analysis using gene expression per tissue based on GTEx RNA-seq data for a) 30 general and b) 53 specific tissue types.
1. Dibner, C. & Schibler, U. Circadian timing of metabolism in animal models and humans. *J. Intern. Med.* **277**, 513–527 (2015).

2. Roenneberg, T. *et al.* Epidemiology of the human circadian clock. *Sleep Med. Rev.* **11**, 429–438 (2007).

3. Horne, J. A. & Ostberg, O. A self-assessment questionnaire to determine morningness-eveningness in human circadian rhythms. *Int. J. Chronobiol.* **4**, 97–110 (1976).

4. Smith, C. S., Reilly, C. & Midkiff, K. Evaluation of Three Circadian Rhythm Questionnaires With Suggestions for an Improved Measure of Morningness. *J. Appl. Psychol.* **74**, 728–738 (1989).

5. Duffy, J. F. & Czeisler, C. A. Age-related change in the relationship between circadian period, circadian phase, and diurnal preference in humans. *Neurosci. Lett.* **318**, 117–120 (2002).

6. Fischer, D., Lombardi, D. A., Marucci-wellman, H. & Roenneberg, T. Chronotypes in the US – Influence of age and sex. 1–17 (2017).

7. Allebrandt, K. V *et al.* Chronotype and sleep duration: the influence of season of assessment. *Chronobiol. Int.* **31**, 731–40 (2014).

8. Leocardio-Miguel, M. A. *et al.* Latitudinal cline of chronotype. *Sci. Rep.* **7**, 2–7 (2017).

9. Takahashi, J. S., Hong, H. K., Ko, C. H. & McDearmon, E. L. The genetics of mammalian circadian order and disorder: Implications for physiology and disease. *Nat. Rev. Genet.* **9**, 764–775 (2008).

10. Schmid, S. M., Hallschmid, M. & Schultes, B. The metabolic burden of sleep loss. *Lancet Diabetes Endocrinol.* **3**, 52–62 (2015).

11. Kohsaka, A. *et al.* High-Fat Diet Disrupts Behavioral and Molecular Circadian Rhythms in Mice. *Cell Metab.* **6**, 414–421 (2007).

12. Marcheva, B. *et al.* Disruption of the clock components CLOCK and BMAL1 leads to hypoinsulinaemia and diabetes. *Nature* **466**, 627–31 (2010).

13. Turek, F. W. *et al.* Obesity and Metabolic Syndrome in Circadian Clock Mutant Mice. *Science* (80-. ). **308**, 1043–1045 (2005).

14. Morris, C. J., Purvis, T. E., Mistretta, J., Hu, K. & Scheer, F. A. J. L. Circadian Misalignment Increases C-Reactive Protein and Blood Pressure in Chronic Shift Workers. *J. Biol. Rhythms* **32**, 154–164 (2017).

15. Wright, K. P. *et al.* Influence of sleep deprivation and circadian misalignment on cortisol, inflammatory markers, and cytokine balance. *Brain.Behav. Immun.* **47**, 24–34 (2015).

16. Skarke, C. *et al.* A pilot characterization of the human chronobiome. *Sci. Rep.* **7**, 1–12 (2017).

17. Patterson, F. *et al.* Interactive effects of sleep duration and morning/evening preference on cardiovascular risk factors. *Eur. J. Public Health* (2017). doi:10.1093/eurpub/ckx029

18. Merikanto, I. *et al.* Associations of Chronotype and Sleep With Cardiovascular Diseases and Type 2 Diabetes. *Chronobiol. Int.* **30**, 470–477 (2013).

19. Levandovski, R. *et al.* Depression Scores Associate With Chronotype and Social Jetlag in a Rural Population. *Chronobiol. Int.* **28**, 771–778 (2011).

20. Vetter, C. *et al.* Mismatch of sleep and work timing and risk of type 2 diabetes. *Diabetes Care* **38**, 1707–1713 (2015).

21. Hu, Y. GWAS of 89,283 individuals identifies genetic variants associated with self-reporting of being a morning person. *Nat. Commun.* **7**, 10448 (2016).

22. Lane, J. M. Genome-wide association analysis identifies novel loci for chronotype in 100,420 individuals from the UK Biobank. *Nat. Commun.* **7**, 10889 (2016).

23. Jones, S. E. *et al.* Genome-Wide Association Analyses in 128,266 Individuals Identifies New Morningness and Sleep Duration Loci. *PLOS Genet.* **12**, e1006125 (2016).

24. Sabia, S. *et al.* Association between questionnaire-and accelerometer-assessed physical activity: The role of sociodemographic factors. *Am. J. Epidemiol.* **179**, 781–790 (2014).

25. Launderdale, D. S., Knutson, K. L., Yan, L. L., Liu, K. & Rathouz, P. J. Self-Reported and Measured Sleep Duration. *Epidemiology* **19**, 838–845 (2008).

26. Slightham, C. *et al.* Assessing sleep quality using self-report and actigraphy in PTSD. *J. Sleep Res.* (2017). doi:10.1111/jsr.12632

27. Cespedes, E. M. *et al.* Comparison of Self-Reported Sleep Duration with Actigraphy: Results from the Hispanic Community Health Study/Study of Latinos Sueno Ancillary Study. *Am. J. Epidemiol.* **183**, 561–573 (2016).

28. Winkelman, J. Genome-wide association study identifies novel restless legs syndrome susceptibility loci on 2p14 and 16q12.1. *PLOS Genet.* **7**, e1002171 (2011).

29. Zhang, L. *et al.* A PERIOD3 variant causes a circadian phenotype and is associated with a seasonal mood trait. *Proc. Natl. Acad. Sci.* **113**, E1536–E1544 (2016).
30. Speliotes, E. K. et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. *Nat. Genet.* **42**, 937–948 (2010).
31. Locke, A. E. et al. Genetic studies of body mass index yield new insights for obesity biology. *Nature* **518**, 197–206 (2015).
32. Huyghe, J. R. et al. Exome array analysis identifies new loci and low-frequency variants influencing insulin processing and secretion. *Nat. Genet.* **45**, 197–201 (2013).
33. de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: Generalized Gene-Set Analysis of GWAS Data. *PLoS Comput. Biol.* **11**, 1–19 (2015).
34. Watanabe, K., Taskesen, E., Bochoven, A. van & Posthuma, D. FUMA: Functional mapping and annotation of genetic associations. *bioRxiv* **3**, 110023 (2017).
35. Lamparter, D., Marbach, D., Rueedi, R., Kutalik, Z. & Bergmann, S. Fast and Rigorous Computation of Gene and Pathway Scores from SNP-Based Summary Statistics. *PLoS Comput. Biol.* **12**, 1–20 (2016).
36. Ayellet, V. S., Groop, L., Mootha, V. K., Daly, M. J. & Altshuler, D. Common inherited variation in mitochondrial genes is not enriched for associations with type 2 diabetes or related glycemic traits. *PLoS Genet.* 6, e1001058 (2010).
37. Pers, T. H. et al. Biological interpretation of genome-wide association studies using predicted gene functions. *Nat. Commun.* **6**, (2015).
38. Zhang, E. E. et al. A Genome-wide RNAi Screen for Modifiers of the Circadian Clock in Human Cells. *Cell* **139**, 199–210 (2009).
39. Hemani, G. et al. MR-Base: a platform for systematic causal inference across the phenome using billions of genetic associations. *bioRxiv* (2016). at <http://bioRxiv.org/content/early/2016/12/16/078972.abstract>.
40. Lawlor, D. A. Commentary: Two-sample Mendelian randomization: opportunities and challenges. *Int. J. Epidemiol.* **45**, 908–915 (2016).
41. Yaghootkar, H. et al. Genetic evidence for a link between favorable adiposity and lower risk of type 2 diabetes, hypertension, and heart disease. *Diabetes* **65**, 2448–60 (2016).
42. Perez-Santángelo, S. et al. Role for LSM genes in the regulation of circadian rhythms. *Proc. Natl. Acad. Sci.* **111**, 15166–15171 (2014).
43. Baker, F. C. & Driver, H. S. Circadian rhythms, sleep, and the menstrual cycle. *Sleep Med.* **8**, 613–622 (2007).
44. Toffol, E. et al. Evidence for a relationship between chronotype and reproductive function in women. *Chronobiol. Int.* **30**, 756–765 (2013).
45. Partonen, T., Toffol, E. & Heikinheimo, O. Biological rhythms and fertility: the hypothalamicus;&ndash;pituitary;&ndash;ovary axis. *Chronopharmacology Ther.* **6**, 15 (2016).
46. Arora, T. & Taheri, S. Associations among late chronotype, body mass index and dietary behaviors in young adolescents. *Int. J. Obes.* **39**, 39–44 (2015).
47. Yu, J. H. et al. Evening chronotype is associated with metabolic disorders and body composition in middle-aged adults. *J. Clin. Endocrinol. Metab.* **100**, 1494–1502 (2015).
48. Vollmers, C. et al. Time of feeding and the intrinsic circadian clock drive rhythms in hepatic gene expression. *Proc. Natl. Acad. Sci.* **106**, 21453–21458 (2009).
49. Eckel-Mahan, K. & Sassone-Corsi, P. Metabolism and the Circadian Clock Converge. *Physiol. Rev.* **93**, 107–135 (2013).
50. Munafò, M. R., Tilling, K., Taylor, A. E., Evans, D. M. & Davey Smith, G. Collider scope: when selection bias can substantially influence observed associations. *Int. J. Epidemiol.* **226**–235 (2017). doi:10.1093ije/dyx206
51. Sudlow, C. UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med.* **12**, e1001779 (2015).
52. Doherty, A. et al. Large Scale Population Assessment of Physical Activity Using Wrist Worn Accelerometers: The UK Biobank Study. *PLoS One* **12**, e0169649 (2017).
53. van Hees, V. et al. Auto-calibration of accelerometer data for free-living physical activity assessment using local gravity and temperature: an evaluation on four continents. *J. Appl. Physiol.* **44**, 738–744 (2014).
54. Van Hees, V. T. et al. A novel, open access method to assess sleep duration using a wrist-worn accelerometer. *PLoS One* **10**, 1–13 (2015).
55. Bycroft, C. et al. Genome-wide genetic data on ~500,000 UK Biobank participants. *Doi.Org* 166298 (2017). doi:10.1101/166298
56. van Hees, V. T. et al. Separating Movement and Gravity Components in an Acceleration Signal and Implications for the Assessment of Human Daily Physical Activity. *PLoS One* **8**, 1–
van Hees, V. T. et al. Estimating sleep parameters using an accelerometer without sleep diary. bioRxiv (2018). at <http://biorxiv.org/content/early/2018/02/01/257972.abstract>

Loh, P.-R. et al. Efficient Bayesian mixed-model analysis increases association power in large cohorts. Nat. Genet. 47, 284–290 (2015).

Price, A. L. et al. Long-Range LD Can Confound Genome Scans in Admixed Populations. Am. J. Hum. Genet. 83, 132–135 (2008).

Willer, C. J., Li, Y. & Abecasis, G. R. \pkg{METAL}: Fast and Efficient Meta-analysis of Genomewide Association Scans. Bioinformatics 26, 2190–2191 (2010).

Bulik-Sullivan, B. K. et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat Genet advance on, 291–295 (2015).

Bowden, J. et al. Assessing the suitability of summary data for two-sample mendelian randomization analyses using MR-Egger regression: The role of the I2statistic. Int. J. Epidemiol. 45, 1961–1974 (2016).

Bowden, J., Davey Smith, G., Haycock, P. C. & Burgess, S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet. Epidemiol. 40, 304–314 (2016).

Burgess, S., Bowden, J., Dudbridge, F. & Thompson, S. G. Robust instrumental variable methods using multiple candidate instruments with application to Mendelian randomization. 1–38 (2016). at <http://arxiv.org/abs/1606.03729>

DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet 44, 981–990 (2012).

Dimas, A. S. et al. Impact of type 2 diabetes susceptibility variants on quantitative glycemic traits reveals mechanistic heterogeneity. Diabetes 63, 2158–2171 (2014).